Nama's AI scorecard currently rates Stryker Buy (6.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is SYK's P/E ratio?

Stryker trades at a trailing price-to-earnings ratio of 22.8.

When does SYK report earnings?

Stryker's next scheduled report is on Jan 28, 2027. Analysts expect EPS of $5.02.

What is the SYK price target?

The median analyst price target from 27 analysts is $334.00, with a range of $275.00 – $465.00.

Is SYK Shariah compliant?

Nama's AAOIFI-style screen reads Stryker as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Does SYK pay a dividend?

Yes — Stryker's dividend yield is 1.1%.

Nama Insights

Stryker (SYK)

Healthcare · Medical Devices · NYSE

S&P 500

Stryker (SYK) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $124.06B, a trailing price-to-earnings ratio of 22.8 and a free-cash-flow yield of 3.4%. Over the most recent reported fiscal year, revenue grew 11.2% and free cash flow per share grew 22.5%. Nama's AI scorecard rates it Buy, 6.6 out of 10. On 12-month momentum it ranks in the trailing band of its market.

AI scorecard

Buy · 6.6/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Trailing · -22.2% over 12 months ex. last

Bottom 20% of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-19.8%

How far the last close sits under the highest price of the past five years.

Market cap	$124.06B
Trailing P/E	22.8
Price / book	5.2
Price / sales	4.7
FCF yield	3.4%
Dividend yield	1.1%
Gross margin	65.0%
Operating margin	21.7%
Net margin	14.4%
Revenue growth (YoY)	+11.2%
Revenue growth (3-yr annual)	+10.8%
EPS growth (YoY)	+11.8%
FCF/share growth (YoY)	+22.5%
Beta	0.8
Exchange	NYSE
Sector	Healthcare
Industry	Medical Devices

SYK earnings

Next report: Jan 28, 2027 (Q4 2026, EPS estimate $5.02). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	$3.52	$3.55	-0.8%	$6.52B
Q2 2026	Jul 30, 2026	$3.69	$3.49	+5.7%	$6.59B
Q1 2026	Apr 30, 2026	$2.60	$2.98	-12.8%	$6.02B
Q4 2025	Jan 29, 2026	$4.47	$4.40	+1.6%	$7.17B

SYK analyst price target

Median target $334.00 from 27 analysts, ranging $275.00 – $465.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7
STE	STERIS	$24.60B	23.2

Explore live SYK data on Nama Insights →

Recent Congressional trades

Stryker trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Thomas H. Kean	House	Sell	$1,001 - $15,000	Oct 30, 2026
Thomas H. Kean	House	Sell	$1,001 - $15,000	Aug 18, 2026
Alan Armstrong	Senate	Sell	$15,001 - $50,000	Jul 21, 2026
Thomas H. Kean	House	Sell	$1,001 - $15,000	Jul 15, 2026
Thomas H. Kean	House	Sell	$15,001 - $50,000	Feb 19, 2026
Julia Letlow	House	Sell	$1,001 - $15,000	Jan 13, 2026
Julia Letlow	House	Buy	$1,001 - $15,000	Jan 13, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Jan 12, 2026
Thomas H. Kean	House	Sell	$15,001 - $50,000	Dec 19, 2025
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Dec 15, 2025
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Nov 18, 2025
Thomas H. Kean	House	Sell	$15,001 - $50,000	Oct 14, 2025

SYK FAQ

Is SYK a buy?: Nama's AI scorecard currently rates Stryker Buy (6.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is SYK's P/E ratio?: Stryker trades at a trailing price-to-earnings ratio of 22.8.
When does SYK report earnings?: Stryker's next scheduled report is on Jan 28, 2027. Analysts expect EPS of $5.02.
What is the SYK price target?: The median analyst price target from 27 analysts is $334.00, with a range of $275.00 – $465.00.
Is SYK Shariah compliant?: Nama's AAOIFI-style screen reads Stryker as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.
Does SYK pay a dividend?: Yes — Stryker's dividend yield is 1.1%.